POTE ankyrin domain family member HGenealiases: A26C3 · ACTBL1 · CT104.7 · POTE22
Q-omics provides the consensus-scored POTEH profile across patient tissues and cancer cell-line models. POTEH expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, POTEH is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, POTEH RNA expression shows 8,814 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, HNSC, and TGCT as cancer lineages where POTEH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTEH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTEH survival associations across molecular data types. POTEH RNA expression shows survival associations in the most cancer types (16), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTEH RNA expression–survival associations across cancer types. High POTEH expression shows unfavorable associations in KICH, LUAD, MESO, DLBC and UCS, but favorable associations in BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for POTEH RNA expression.
This table summarizes POTEH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for POTEH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTEH shows higher tumor expression in HNSC, LUSC, BRCA, PRAD and LIHC. The HNSC box plot shows higher POTEH RNA expression in tumor versus normal tissue (log2 FC = +0.031, t-test p = .035).
This table shows molecular features associated with POTEH in patient tissues and cancer cell lines. In patient samples, POTEH shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, POTEH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SOFT_TISSUE.
